Acquire the license to the best health content in the world
Contact Us

Dysglycemia Risk Up for Women With PCOS, Regardless of BMI

Combined oral contraceptive pill use associated with reduced dysglycemia risk for women with PCOS

reproductive system in woman
Adobe Stock

FRIDAY, Oct. 22, 2021 (HealthDay News) -- Women with polycystic ovary syndrome (PCOS) have an increased risk for dysglycemia in all body mass index (BMI) subgroups, and combined oral contraceptive pill (COCP) use is associated with a reduced dysglycemia risk, according to a study published online Oct. 14 in Diabetes Care.

Balachandran Kumarendran, M.B.B.S., from the University of Birmingham in the United Kingdom, and colleagues conducted a retrospective population-based cohort study to examine dysglycemia risk among 64,051 women with PCOS and 123,545 matched controls and a nested pharmacoepidemiological case-control study to examine COCP use in relation to the risk for dysglycemia (2,407 women with PCOS with and without a diagnosis of dysglycemia during follow-up [cases and controls]).

The researchers found that after adjustment for age, social deprivation, BMI, ethnicity, and smoking, the hazard ratio for dysglycemia was 1.87 for women with PCOS; the rates of dysglycemia were increased in all BMI subgroups. Reduced dysglycemia risk was seen for women with PCOS and COCP use (adjusted odds ratio, 0.72).

"Women with PCOS have a significantly increased risk of dysglycemia that persisted after adjustment for BMI, corroborating the recommendation that women with PCOS should be systematically screened for type 2 diabetes irrespective of body weight category," the authors write. "In our nested pharmacoepidemiology study, we found that women with PCOS and exposure to COCPs had a lower risk of incident dysglycemia."

Abstract/Full Text (subscription or payment may be required)

Physician's Briefing